Cathepsin H is a lysosomal cysteine protease that may participate in tumor progression. In order to evaluate its potential as a prognostic marker, its protein levels were measured by ELISA in preoperative sera from 324 patients with colorectal cancer. The level of cathepsin H was significantly increased in patient sera, the median level was 8.4 ng/mL versus 2.1 ng/mL in 90 healthy blood donors (p<0.0001). A weak association of cathepsin H levels was found with patient age (p=0.02) but not with Dukes' stage, sex, or the level of carcinoembryonic antigen (CEA). In survival analysis a significant difference was found between the group of patients with low cathepsin H (first tertile) who had a poor prognosis and the remaining patients (p=0.03). The risk of patients was further stratified when cathepsin H levels were combined with CEA. Patients with high CEA and low cathepsin H had the highest risk of death with a hazard ratio of 2.72 (95% CI 1.73-4.28), p<0.0001. Our results show that the prognostic information of cathepsin H differs from that of the related cathepsins B and L and suggest different roles during the progression of malignant disease. (Int J Biol Markers 2004; 19: 289-94)
INTRODUCTION
Lysosomal cysteine proteases, generally known as cathepsins, have been viewed as mediators of unspecific lysosomal protein degradation. However, there is accumulating evidence that even ubiquitously expressed cathepsins are involved in some more specialized processes, including apoptosis, MHC class II immune responses, pro-hormone processing, and bone remodelling and may therefore be implicated in the development and progression of a variety of human diseases (1, 2) . Their increased levels in tumors and extracellular fluids of many cancer types have been found to be associated with the length of survival and may therefore serve as prognostic factors for cancer patients. However, studies mainly focused on cathepsins B and L, whereas the role of other cathepsins in malignant progression has been much less described.
Cathepsin H, for example, showed a very different behavior among tumor types. In some tumors, such as breast carcinoma, glioblastoma and anaplastic astrocytoma, increased protein levels of cathepsin H have been observed compared to control tissue (3, 4) . On the other hand, decreased levels of cathepsin H were measured in melanocytic lesions (5) , head and neck (6) and lung tumors (7) . Interestingly, in the latter study a significant difference in cathepsin H levels between lung tumor tissue and non-tumorous lung parenchyma was associated with the group of cigarette smokers. For smokers cathepsin H levels correlated with survival rate, while for the entire population this was not the case. However, cathepsin H was significantly higher in sera of the entire patient population compared to controls (7) . High serum levels of cathepsin H were found also in patients with breast cancer and melanoma (4, 8) . In melanoma patients cathepsin H has been put forward as a prognostic marker since patients with high cathepsin H serum levels had a significantly shorter overall survival than patients with low levels of the enzyme (8) .
The aim of the present study was to evaluate the prognostic significance of cathepsin H as a marker of overall survival in colorectal cancer. For this purpose we determined the levels of this enzyme in preoperatively collected sera of patients with colorectal cancer using a quantitative immunosorbent assay (ELISA). Cathepsin H levels were compared with those of CEA, an established tumor marker in colorectal carcinoma (9) , and other factors associated with the progression of the disease.
MATERIALS AND METHODS

Patients
Three hundred twenty-four patients with histologically verified colorectal cancer were included in the study. Clinical data such as age, sex, Dukes' stage and survival after the operation were registered for each patient. As control, sera from 90 healthy blood donors were included (10) . The median age at operation was 68 years (range 35-90 years). None of the patients received pre-or postoperative radiotherapy or postoperative adjuvant therapy. All patients were seen and examined when required every third month after resection. The median follow-up period was 7.9 years (range 6.8-9.1). Thanks to the computerized Central Personal Registration number given to all Danes, no patient was lost to follow-up. Two hundred and sixteen patients died of any cause, 54 developed local recurrences and 39 distant metastases. The patients' characteristics are shown in Table I .
Sample collection
Five-mL blood samples were collected preoperatively from patients scheduled to undergo elective colorectal cancer surgery. Blood was clotted at 4-8º C and subsequently centrifuged at 3000 rpm. Sera were stored at -80º C until analyzed.
Determination of Cathepsin H and CEA
Human cathepsin H was analyzed by means of an ELISA (KRKA d.d., Novo mesto, Slovenia). The test was optimized and performed as described (11) . Cathepsin H protein was expressed in ng/mL. The detection limit of the assay was 2 ng/mL. Sera were used in 1:2 dilution.
CEA serum levels were determined by the Immulite CEA assay (EURO/PPC Ltd.) according to the instructions of the manufacturer. CEA protein was expressed in ng/mL of serum. When serum CEA levels exceeded the range of the standard curve, the sample was further diluted and reanalyzed.
Statistical methods
For descriptive statistics the SPSS PS software was used (Release 6.0; SPSS Inc., Chicago, IL, USA). The differences in cathepsin H content between two or more groups were tested using rank sum tests.
For analysis of survival, the SAS software (Release 8.2, SAS Institute Inc., Cary, NC, USA) was used. For cathepsin H the patients were grouped by tertiles and for CEA according to a cutoff of 5.0 ng/mL (12) . Survival curves were estimated using the product limit method of and homogeneity between strata was tested using the log-rank test. Cox's proportional hazards model was used for multivariate analysis (14) . In all tests two-sided p vales below 5% were considered significant.
RESULTS
Distribution of cathepsin H and CEA
The level of cathepsin H was significantly increased in sera of patients with colorectal cancer when compared to healthy blood donors. The medians were 8.4 ng/mL (range, 2.0-125 ng/mL) and 2.1 ng/mL (range, 2.0-82.9 ng/mL), respectively (p<0.0001). Patients were grouped by tertiles defining low, median and high values of cathepsin H. Distribution of low, median and high values of cathepsin H by Dukes' stage, gender and tumor location is shown in Tables II and III and reveals no association with these parameters. There was a weak but sta- 
Survival analysis
Kaplan-Meier curves representing the survival probability rates of patients with low, medium and high cathepsin H levels are presented in Figure 1 . Patients with low levels of cathepsin H had the highest risk of death, significantly different from that of the group of patients with medium cathepsin H levels (p=0.03, hazard ratio (HR) 0.74, 95% confidence interval (CI) 0.56-0.98). In multivariate analysis including Dukes' stage, tumor location, gender and age, cathepsin H did not provide any significant prognostic information (Tab. IV). However, cathepsin H was significant in the multivariate model when the analysis was restricted to three years (p=0.03, HR=0.65, 95% CI 0.44-0.96), showing that its prognostic information is related to the follow-up period.
To study the prognostic significance of CEA in univariate and multivariate analysis, we dichotomized the levels into a high and a low group using a cutoff value of 5 ng/mL. Patients with CEA levels below or equal to the cutoff showed a significantly lower risk of death than those with high CEA levels (HR=2.23, 95% CI 1.7-2.92, p<0.0001) (Fig. 2) . We wondered whether the combination of CEA and cathepsin H would increase the prognostic stratification of the patients. Adding CEA to cathepsin H showed significance for both covariates (for cathepsin H: p=0.01, HR=0.69, 95% CI 0.52-0.92 and for CEA: p<0.0001, HR=2.31, 95% CI 1.77-3.03). In this case cathepsin H was scored by the first tertile vs others and Kaplan-Meier curves for four different combinations are shown in Figure 3 . Taking Combination of CEA and cathepsin H did not provide significant prognostic information in multivariate analysis. Furthermore, CEA and cathepsin H were not significant for prognosis when local or distant recurrences were taken as endpoints in univariate or multivariate analysis. 
DISCUSSION
Colorectal carcinoma is the second most common cause of cancer mortality (15) and the most salient risk factors are age and diet. Although for this type of malignancy the most powerful predictor of final outcome remains the Dukes classification, it is not fully successful at predicting recurrence and survival risks for patients with Dukes' stage B (16) . Additional markers are needed to identify patients with a high risk of recurrence of the disease, to assess the response to treatment, and to provide a signal of relapse or disease recurrence (17) . Among several colorectal cancer tumor markers CEA is the most widely used (18) . However, its use as a guide in clinical practice is limited because of the rather low sensitivity, non-tumor related changes in serum levels, different secretion rates of individual tumors and the association with Dukes' stage (17, 19, 20) .
Tumor tissue and serum levels of the cysteine proteases cathepsin B and L have been shown to correlate with survival of patients with different cancer types, including colorectal cancer (1, 8, (21) (22) (23) . These studies led us to consider another cysteine protease, cathepsin H, as a candidate tumor marker in colorectal cancer. The levels of this enzyme in extracellular fluids such as serum and the correlation with patient survival had our particular interest.
Apart from some divergent results most previous studies reported lower levels of cathepsin H in tumors than in adjacent control tissues, whereas the levels in blood of cancer patients were higher compared to controls. This apparently contradictory result can be explained by a recent study of Waghray et al (24) showing that in prostate tumor cells besides a wild-type form a truncated form of cathepsin H is present with a 12amino-acid deletion in its signal peptide region. This deletion affects the trafficking of cathepsin H and may significantly increase its secretion from tumor cells. Therefore, one may expect that the extracellular level of cathepsin H could reflect the progression of malignant disease. Indeed, as shown in our previous study on metastatic melanoma patients, elevated serum levels correlated with a short patient survival (8) . Cathepsin H levels also predicted the effectiveness of chemo-immunotherapy, cathepsn H being higher in non-responders than in responders (8) . On the other hand, in melanocytic lesions lower activity and immunoreactivity levels have been found than in the dermis of normal skin (5) . Higher levels of cathepsin H were detected in serum of patients with lung cancer than in serum of healthy controls, whereas in tumor tissue extracts cathepsin H was significantly lower than in adjacent lung tissue (7) .
This study on 324 patients with colorectal cancer also demonstrates a significant increase in cathepsin H level in patient sera compared with sera from healthy controls. The serum levels of cathepsin H showed no association with the stage of the disease. In contrast to our results, del Re et al (25) demonstrated in tumor tissue extracts of colorectal cancer patients an association of increased cathepsin H activity levels with Dukes' B and C carcinoma. They also proposed a correlation between elevated cathepsin H activity and the processes of local or lymph node invasion.
Survival analysis of the serum levels of cathepsin H showed no significant difference in the risk of death when patients were separated into two groups using the median level as cutoff value. However, a significant difference was observed when patients were grouped by tertiles. Patients with low cathepsin H levels (first tertile) had a significantly lower survival probability rate than those with moderate or high cathepsin H levels (second and third tertile, respectively). The stratification of patients into high and low risk groups was even more significant when cathepsin H was combined with CEA. In this case patients with high CEA levels and low cathepsin H levels (first tertile) proved to have the highest risk of death.
We have no clear explanation of why increased levels of serum cathepsin H are associated with good pa-tient outcome. However, this result may reflect a multifunctional role of cathepsin H. It is possible that cathepsin H participates not only in tumor-promoting degradation of extracellular matrix but also in not yet studied tumor-opposing processes. In this case the concentration level defines which of the two roles is predominant and thus directs the process towards tumor progression or regression. For example, like other cathepsins it could mediate tumor cell apoptosis (26) or immune response (27) and thus counteract tumor progression. However, further studies are clearly needed to evaluate these possibilities.
In conclusion, our results show that cathepsin H provides prognostic information which is different from that of the related cathepsins B and L. We found that patients with low serum levels of cathepsin H had a high risk of death. For this group of patients the risk could be further stratified by adding CEA to the analysis; patients with high CEA and low cathepsin H had the lowest survival probability rate.
